26
|
Marlet J, Ankri A, Charuel J, Ghillani-Dalbin P, Perret A, Martin-Toutain I, Haroche J, Amoura Z, Musset L, Miyara M. Anticorps anti-DFS70 et thrombophilie. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
27
|
Gitiaux C, De Antonio M, Aouizerate J, Gherardi R, Guilbert T, Barnerias C, Bodemer C, Brochard-Payet K, Quartier P, Musset L, Chazaud B, Desguerre I, Bader-Meunier B. Vasculopathy as a major marker of severity in juvenile dermatomyositis. Neuromuscul Disord 2015. [DOI: 10.1016/j.nmd.2015.06.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Gallay L, Mariampillai K, Charuel J, Hervier B, Herson S, Musset L, Benveniste O. Marqueurs immunologiques sériques dans une cohorte de 89 patients atteints de myosite à inclusions. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.030] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Aussy A, Drouot L, Benveniste O, Musset L, Charuel J, Jouen F, Marie I, Boyer O. Mise au point d’un test de dosage et caractérisation des anticorps anti-TIF1gamma au cours des dermatomyosites paranéoplasiques. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
30
|
Mauhin W, Schoindre Y, Stojkovic T, Champtiaux N, Mariampillai K, Rigolet A, Miyara M, Charuel J, Herson S, Musset L, Benveniste O. Anticorps anti-mitochondrie et myopathies inflammatoires. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Keraen J, Champtiaux N, Schoindre Y, Mariampillai K, Rigolet A, Musset L, Herson S, Allenbachyves Y, Hervier B, Benveniste O. Possible sur-risque de survenue de cancers synchrones au cours des myosites nécrosantes auto-immunes à anti-HMGCR. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Jouenne R, Chader D, Cohen Aubart F, Haroche J, Mathian A, Musset L, Gorochov G, Amoura Z, Miyara M. Réponse des lymphocytes T régulateurs à des hautes doses de méthylprednisolone au cours du lupus systémique. Rev Med Interne 2014. [DOI: 10.1016/j.revmed.2014.10.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
33
|
Jolly M, Galicier L, Aumaître O, Francès C, Le Guern V, Lioté F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Boutin D, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacré K, Fain O, Stirnemann J, Cacoub P, Jallouli M, Leroux G, Cohen-Bittan J, Tanguy ML, Hulot JS, Musset L, Amoura Z, Piette JC, Costedoat-Chalumeau N. FRI0434 Blood Hydroxychloroquine (HCQ) Levels do not PREDICT Quality of Life in Systemic Lupus Erythematosus (SLE). Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, Bossuyt X, Musset L, Cervera R, Plaza-Lopez A, Dias C, Sousa MJ, Radice A, Eriksson C, Hultgren O, Viander M, Khamashta M, Regenass S, Andrade LEC, Wiik A, Tincani A, Rönnelid J, Bloch DB, Fritzler MJ, Chan EKL, Garcia-De La Torre I, Konstantinov KN, Lahita R, Wilson M, Vainio O, Fabien N, Sinico RA, Meroni P, Shoenfeld Y. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2013; 73:17-23. [PMID: 24126457 DOI: 10.1136/annrheumdis-2013-203863] [Citation(s) in RCA: 371] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) for decades. As the demand for ANA testing increased, alternative techniques were developed challenging the classic IIFA. These alternative platforms differ in their antigen profiles, sensitivity and specificity, raising uncertainties regarding standardisation and interpretation of incongruent results. Therefore, an international group of experts has created recommendations for ANA testing by different methods. Two groups of experts participated in this initiative. The European autoimmunity standardization initiative representing 15 European countries and the International Union of Immunologic Societies/World Health Organization/Arthritis Foundation/Centers for Disease Control and Prevention autoantibody standardising committee. A three-step process followed by a Delphi exercise with closed voting was applied. Twenty-five recommendations for determining ANA (1-13), anti-double stranded DNA antibodies (14-18), specific antibodies (19-23) and validation of methods (24-25) were created. Significant differences between experts were observed regarding recommendations 24-25 (p<0.03). Here, we formulated recommendations for the assessment and interpretation of ANA and associated antibodies. Notably, the roles of IIFA as a reference method, and the importance of defining nuclear and cytoplasmic staining, were emphasised, while the need to incorporate alternative automated methods was acknowledged. Various approaches to overcome discrepancies between methods were suggested of which an improved bench-to-bedside communication is of the utmost importance. These recommendations are based on current knowledge and can enable harmonisation of local algorithms for testing and evaluation of ANA and related autoantibodies. Last but not least, new more appropriate terminologies have been suggested.
Collapse
|
35
|
Allenbach Y, Rigolet A, Drouot L, Charuel J, Jouen F, Jouen F, Maisonobe T, Dubourg O, Behin A, Eymard B, Laforet P, Stojkovic T, Konepaut I, Konepaut I, Cacoub P, Kieffer P, Fain O, Cosserat J, Morati L, Salort E, Menard D, Antoine J, Tournadre A, Menier VB, Ferrer X, Laroche C, Musset L, Herson S, Boyer O, Benveniste O. P.14.11 Auto-immune necrotizing myopathies with anti-HMGCR antibodies are related to statin-exposure only for a minority of cases. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
36
|
Bloch Queyrat C, Rigolet A, Allenbach Y, Musset L, Treluyer J, Urien S, Benveniste O. P.14.8 Ethnic origins influence the natural history modelling of necrotizing myopathy with anti-SRP antibodies. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Allenbach Y, Leroux G, Uzuhnan Y, Valeyre D, Saadoun D, Aubart F, Hervier B, Hie M, Wipff J, Myiara M, Charuel J, Musset L, Audia S, Devillier H, Bonnote B, Barete S, Nimal N, Rigolet A, Herson S, Benveniste O. P.14.2 Dermatomyositis associated with MDA-5 antibodies: Report of the first European series. Neuromuscul Disord 2013. [DOI: 10.1016/j.nmd.2013.06.610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
38
|
Ayrignac X, Viala K, Koutlidis RM, Taïeb G, Stojkovic T, Musset L, Léger JM, Fournier E, Maisonobe T, Bouche P. Sensory chronic inflammatory demyelinating polyneuropathy: An under-recognized entity? Muscle Nerve 2013; 48:727-32. [DOI: 10.1002/mus.23821] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/12/2013] [Indexed: 11/08/2022]
|
39
|
Pham F, Charuel JL, Ghillani-Dalbin P, Hervier B, Allenbach Y, Nunes H, Valeyre D, Amoura Z, Benveniste O, Musset L, Miyara M. L’absence de fluorescence cytoplasmique dans les cellules HEp-2 est rare en présence d’anticorps anti-synthétase ou d’anti-SRP au cours des myopathies inflammatoires et des pneumopathies interstitielles. Rev Med Interne 2013. [DOI: 10.1016/j.revmed.2013.03.284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Saadoun D, Terrier B, Bannock J, Vazquez T, Massad C, Kang I, Joly F, Rosenzwajg M, Sene D, Benech P, Musset L, Klatzmann D, Meffre E, Cacoub P. Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation. ACTA ACUST UNITED AC 2013; 65:1085-96. [PMID: 23279883 DOI: 10.1002/art.37828] [Citation(s) in RCA: 157] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Accepted: 12/07/2012] [Indexed: 11/07/2022]
Abstract
OBJECTIVE Primary Sjögren's syndrome (SS) is an autoimmune disease associated with a high risk of developing non-Hodgkin's lymphoma. This study was undertaken to determine the nature of B cells driving lymphoproliferation in primary SS. METHODS B cell subsets and function were analyzed in peripheral blood from 66 adult patients with primary SS (including 14 patients with B cell lymphoproliferative disease [LPD]) and 30 healthy donors, using flow cytometry, calcium mobilization, and gene array analysis. The reactivity of recombinant antibodies isolated from single B cells from patients with primary SS and LPD was tested using an enzyme-linked immunosorbent assay. RESULTS We observed an expansion of an unusual CD21-/low B cell population that correlated with lymphoproliferation in patients with primary SS. A majority of CD21-/low B cells from patients with primary SS expressed autoreactive antibodies, which recognized nuclear and cytoplasmic structures. These B cells belonged to the memory compartment, since their Ig genes were mutated. They were unable to induce calcium flux, become activated, or proliferate in response to B cell receptor and/or CD40 triggering, suggesting that these autoreactive B cells may be anergic. However, CD21-/low B cells from patients with primary SS remained responsive to Toll-like receptor (TLR) stimulation. Molecules specifically expressed in CD21-/low B cells that are likely to induce their unresponsive stage were detected in gene array analyses. CONCLUSION Patients with primary SS who display high frequencies of autoreactive and unresponsive CD21-/low B cells are susceptible to developing lymphoproliferation. These cells remain in peripheral blood controlled by functional anergy instead of being eliminated, and chronic antigenic stimulation through TLR stimulation may create a favorable environment for breaking tolerance and activating these cells.
Collapse
|
41
|
Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, Pialoux G, Karras A, Bazin-Karra D, Cazorla C, Vittecoq D, Musset L, Decaux O, Ziza JM, Lambotte O, Cacoub P. Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2013; 73:831-7. [PMID: 23606708 PMCID: PMC3995244 DOI: 10.1136/annrheumdis-2012-202770] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Background The standard-of-care treatment of patients with hepatitis C virus (HCV)-mixed cryoglobulinemia (MC) vasculitis includes pegylated interferon α (PegIFN)-α plus ribavirin and/or rituximab. About 30–40% of patients are non-responders or relapsers to such combination. Objective To analyse the safety and efficacy of Peg-IFNα/ribavirin/protease inhibitor combination in HCV-MC vasculitis. Patients and methods Open-label, prospective, cohort study including 23 patients with HCV-MC vasculitis. Peg-IFNα/ribavirin was associated to telaprevir (375 mg three times daily, for 12 weeks, (n=15)) or boceprevir (800 mg three times daily, for 44 weeks, (n=8)) for 48 weeks. Results The median age was 59 (52.5–66) years, with 48.8% women. Thirteen patients (56.5%) were complete clinical responders, and 10 (43.5%) were partial responders at week 24. The virological response (ie, HCV RNA negativation) was of 69.6% at week 24 (p=0.005). The cryoglobulin level decreased from 0.44 to 0.06 g/l (p=0.0006) and the C4 level increased from 0.09 to 0.15 g/l (p=0.045). Grades 3 and 4 adverse events (mainly anaemia, neutropenia and thrombocytopenia) were observed in 10 cases (43.5%). Twenty patients (87%) received erythropoietin, 9 (39.1%) had red cell transfusion, and 2 (8.7%) had granulocyte stimulating agents. Antiviral therapy discontinuation was required in 8 (34.7%) patients for virological non-response (n=5), virological relapse (n=2) and depression (n=1). Conclusions Peg-IFNα/ribavirin/protease inhibitor combination seems highly effective in HCV-MC. Such therapeutic regimen should be administered cautiously considering the high rate of side effects.
Collapse
|
42
|
Mathian A, Devilliers H, Krivine A, Costedoat-Chalumeau N, Haroche J, Huong DBLT, Wechsler B, Hervier B, Miyara M, Morel N, Le Corre N, Arnaud L, Piette JC, Musset L, Autran B, Rozenberg F, Amoura Z. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. ACTA ACUST UNITED AC 2013; 63:3502-11. [PMID: 21811996 DOI: 10.1002/art.30576] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To assess the factors influencing the efficacy of 2 injections of a pandemic 2009 influenza A (H1N1) vaccine in patients with systemic lupus erythematosus (SLE). METHODS We conducted a single-center, observational prospective study of 111 patients who were vaccinated with a monovalent, inactivated, nonadjuvanted, split-virus vaccine during December 2009 and January 2010 and received a second dose of vaccine 3 weeks later. The antibody response was evaluated using the hemagglutination inhibition assay according to the guidelines recommended for the pandemic vaccine, consisting of 3 immunogenicity criteria (i.e., a seroprotection rate of 70%, a seroconversion rate of 40%, and a geometric mean ratio [GMR] of 2.5). RESULTS The 3 immunogenicity criteria were met on day 42 (seroprotection rate 80.0% [95% confidence interval (95% CI) 72.5-87.5%], seroconversion rate 71.8% [95% CI 63.4-80.2%], and GMR 10.3 [95% CI 2.9-14.2]), while only 2 criteria were met on day 21 (seroprotection rate 66.7% [95% CI 57.9-75.4%], seroconversion rate 60.4% [95% CI 51.3-69.5%], and GMR 8.5 [95% CI 3.2-12.0]). The vaccine was well tolerated. Disease activity, assessed by the Safety of Estrogens in Lupus Erythematosus National Assessment version of the SLE Disease Activity Index, the British Isles Lupus Assessment Group score, and the Systemic Lupus Activity Questionnaire, did not increase. In the multivariate analysis, vaccination failure was significantly associated with immunosuppressive treatment or a lymphocyte count of ≤ 1.0 × 10⁹/liter. The second injection significantly increased the immunogenicity in these subgroups, but not high enough to fulfill the seroprotection criterion in patients receiving immunosuppressive treatment. CONCLUSION Our findings indicate that the efficacy of the vaccine was impaired in patients who were receiving immunosuppressive drugs or who had lymphopenia. A second injection increased vaccine immunogenicity without reaching all efficacy criteria for a pandemic vaccine in patients receiving an immunosuppressive agent. These results open possibilities for improving anti-influenza vaccination in SLE.
Collapse
|
43
|
Drouot L, Charuel JL, Jouen F, Allenbach Y, Miyara M, Musset L, Benveniste O, Boyer O. Nouvelle approche diagnostique pour la détection et le dosage des autoanticorps anti-HMGCoA réductase dans les myopathies nécrosantes. Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Allenbach Y, Rigolet A, Guiguet M, Marie I, Hachulla E, Mariampillai K, Jacquot S, Jouen F, Boyer O, Musset L, Herson S, Benveniste O. Efficacité du rituximab pour le des myopathies inflammatoires réfractaires associées aux anticorps anti-histidyl-tRNA synthétases (Étude FORCE-Jo1). Rev Med Interne 2012. [DOI: 10.1016/j.revmed.2012.10.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Ghillani P, Dufat L, Himeur S, Miyara M, Amoura Z, Musset L. Routine use of Zenit RA, a novel chemiluminescent immunoanalyzer in autoimmune disease diagnosis. AUTO- IMMUNITY HIGHLIGHTS 2012; 3:27-31. [PMID: 26000125 PMCID: PMC4389018 DOI: 10.1007/s13317-012-0032-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/26/2011] [Accepted: 03/09/2012] [Indexed: 12/17/2022]
Abstract
The detection of antibodies is useful to diagnose and/or to classify autoimmune diseases as connective tissue diseases and vasculitis. Zenit RA is a fully automated immunoanalyzer. The aim of this study was to compare the predictive and discriminative performance of the Zenit RA anti-cyclic citrullinated peptide (CCP), anti-cardiolipin (aCL) and anti-β 2 glycoprotein 1 (aB2GP1) tests to conventional ELISAs on clinically well-defined groups of patients and to daily evaluate the determination of anti-extractable nuclear antigen (ENA), anti-double stranded DNA (dsDNA), anti-myeloperoxidase (MPO) and anti-proteinase 3 (PR3) antibodies in a hospital laboratory. Reagents available on Zenit RA analyzer exhibit good diagnostic performances, regarding sensitivity, specificity, positive and negative predictive values. Global agreements between Zenit RA and conventional tests were from 90 to 98 % (Kappa-values ranging 0.56-0.94): 96 % for anti-CCP, 90-94 % for aCL and aB2GP1, 94 % for anti-dsDNA, 97 % for anti-ENA, 98 % for anti-MPO and 95 % for anti-PR3 antibodies. Zenit RA analyzer is easy to rapidly detect the most common autoantibodies in autoimmune diseases. This system has a potential to provide clinically useful data within a short time. Because of the flexibility of its work modalities, it is well adapted to determine antigenic specificities in daily practice.
Collapse
|
46
|
Miyara M, Diemert MC, Amoura Z, Musset L. Anticorps antiphospholipides en pratique. Rev Med Interne 2012; 33:176-80. [DOI: 10.1016/j.revmed.2011.09.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2011] [Accepted: 09/27/2011] [Indexed: 11/30/2022]
|
47
|
Miyara M, Arnaud L, Dufat L, Ankri A, Mathian A, Haroche J, Boutin-Le Thi Huong D, Ghillani-Dalbin P, Costedoat-Chalumeau N, Piette J, Musset L, Amoura Z. Les titres d’anticorps antiphosphatidylsérine/prothrombine (aPS/PT) sont fortement corrélés aux tests de recherche d’anticoagulants circulants lupiques chez les patients ayant des anticorps antiphospholipides. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
48
|
Miyara M, Chader D, Musset L, Gorochov G, Amoura Z. Détermination des conditions de culture permettant l’expansion de Tregs naïfs exprimant fortement et durablement FOXP3 in vitro à des fins thérapeutiques dans les maladies auto-immunes systémiques. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
49
|
Bloch-Queyrat C, Drouot L, Charuel J, Yada E, Urien S, Musset L, Boyer O, Benveniste O. Rôle pathogénique des anticorps anti-SRP (signal recognition particle) au cours des myopathies nécrosantes associées. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|
50
|
Miyara M, Arnaud L, Dufat L, Ankri A, Mathian A, Haroche J, Boutin-Le Thi Huong D, Ghillani-Dalbin P, Costedoat-Chalumeau N, Piette J, Musset L, Amoura Z. La présence simultanée d’IgG et d’IgM anti-phosphatidylsérine/prothrombine pourrait être associée à l’occurrence de syndromes catastrophiques des antiphospholipides chez les patients porteurs d’anticorps antiphospholipides. Rev Med Interne 2011. [DOI: 10.1016/j.revmed.2011.10.337] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
|